A glimpse into OrbiMed Advisors’ recent moves in the healthcare space.
How Do Biotech’s Movers and Shakers Fare Under Puravida Funds’ Healthcare-Centric Trading Strategy?
Edward Nash Sees Otonomy as a Pure Speculative Pharma Play
Hedge Fund Guru Mark Kingdon Isn’t Taking Any Risks with OTIC, SGYP, ATRS
Wednesday turned out to be a nightmare for Otonomy Inc (NASDAQ:OTIC) investors, after the drug maker announced disappointing results from a pivotal Phase …
